BIOLASE, Inc.Find Ratings Reports
BIOLASE INC's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the subsector, the net income growth did not. BIOLASE INC has strong liquidity. Currently, the Quick Ratio is 2.00 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 130.95% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||8.52||10.18|
|Net Income ($mil)||-6.14||-3.57|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||17.88||6.1|
|Total Assets ($mil)||41.03||31.85|
|Total Debt ($mil)||18.27||13.79|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||18.51||45.62|
|Return on Assets||-41.02||-56.06|
|Return on Equity||-341.11||-411.22|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||97.66||31.44|
|Div / share||0.0||0.0|
|Book value / share||0.1||0.14|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1.1927661E7||3.0140734E7|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.40 indicates a significant premium versus the S&P 500 average of 4.43 and a significant discount versus the subsector average of 10.37. The price-to-sales ratio is above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives.
|BIOL NM||Peers 129.08||BIOL NM||Peers 78.57|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BIOL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BIOL's P/CF is negative making the measure meaningless.
|BIOL NM||Peers 62.45||BIOL NA||Peers 2.99|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BIOL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BIOL 7.40||Peers 10.37||BIOL 25.32||Peers 15.52|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BIOL is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
BIOL is expected to have an earnings growth rate that significantly exceeds its peers.
|BIOL 3.26||Peers 11.84||BIOL -39.74||Peers 16.54|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BIOL is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
BIOL significantly trails its peers on the basis of sales growth.